Principles of psychoneuroendocrinoimmunotherapy of cancer. (Q37965753)

26 August 2017

title

Principles of psychoneuroendocrinoimmunotherapy of cancer. (English)

1 reference

26 August 2017

Paolo Lissoni

1 reference

26 August 2017

Franco Rovelli

series ordinal

1 reference

26 August 2017

publication date

1 January 2012

1 reference

26 August 2017

1 reference

26 August 2017

1 reference

26 August 2017

1 reference

26 August 2017

page(s)

77-86

1 reference

Suppressor Cells in Neoplastic Disease

26 August 2017

cites work

1 reference

https://api.crossref.org/works/10.2217%2FIMT.11.158

Regulatory T cells, tumour immunity and immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.11.158

Karnofsky Memorial Lecture. The immunotherapy and gene therapy of cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.11.158

Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.11.158

Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.11.158

Five-year cancer cure: relation to total amount of peripheral lymphocytes and neutrophils

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.11.158

In vivo stimulation of IL-12 secretion by subcutaneous low-dose IL-2 in metastatic cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.11.158

The influence of bio-behavioural factors on tumour biology: pathways and mechanisms

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.11.158

Biobehavioral influences on cancer progression

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.11.158

Neuroendocrine-immune mechanisms of behavioral comorbidities in patients with cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.11.158

Lymphokine-activated killer cell phenomenon. Lysis of natural killer-resistant fresh solid tumor cells by interleukin 2-activated autologous human peripheral blood lymphocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.11.158

Interleukin 12: a new clinical player in cytokine therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.11.158

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.11.158

T(H)-17 cells in the circle of immunity and autoimmunity

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.11.158

Dendritic cells: from ontogenetic orphans to myelomonocytic descendants.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.11.158

Natural regulatory T cells and self-tolerance

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.11.158

beta-Endorphin: characterization of binding sites specific for the human hormone in human glioblastoma SF126 cells

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.11.158

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.11.158

Apparent involvement of opioid peptides in stress-induced enhancement of tumor growth

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.11.158

Effects of tetrahydrocannabinol on melatonin secretion in man.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.11.158

The immunoneuroendocrine role of melatonin

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.11.158

Antiproliferative effect of pineal indoles on cultured tumor cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.11.158

5-Methoxyindoles in pineal gland of cow, pig, sheep and rat

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.11.158

A sequential treatment regimen with melatonin and all-trans retinoic acid induces apoptosis in MCF-7 tumour cells

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.11.158

Is there a role for melatonin in supportive care?

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.11.158

Circadian-system alterations during cancer processes: a review

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.11.158

Cancer, cytokines, and cytotoxic cells: interleukin-2 in the immunotherapy of human neoplasms

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.11.158

Second line therapy with low-dose subcutaneous interleukin-2 alone in advanced renal cancer patients resistant to interferon-alpha

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.11.158

Multicenter phase 2 study of interleukin-2 and 13-cis retinoic acid as maintenance therapy in advanced non-small-cell lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.11.158

The clinical neuroimmunotherapeutic role of melatonin in oncology

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.11.158

A randomised study with subcutaneous low-dose interleukin 2 alone vs interleukin 2 plus the pineal neurohormone melatonin in advanced solid neoplasms other than renal cancer and melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.11.158

Characterization of CD4+CD25+ regulatory T cells in patients treated with high-dose interleukin-2 for metastatic melanoma or renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.11.158

21 January 2018

Identifiers

DOI

10.2217/IMT.11.158

1 reference

26 August 2017

1 reference